清肺排毒汤加减方联合抗病毒药物治疗新型冠状病毒肺炎的回顾性研究

目的回顾性评价清肺排毒汤加减方治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法选取2020年1月24日—2020年3月7日在湖北省第三人民医院就诊的符合COVID-19确诊标准的出院病历资料60例,按照治疗方法的不同分为对照组和联合用药组,联合用药组30例采用常规治疗(营养支持、呼吸支持、抗病毒药物治疗)联合清肺排毒汤加减方,对照组30例仅采用常规治疗,比较两组患者临床治愈率、主要症状消失时间及有关检测指标好转时间。结果联合用药组患者住院天数显著低于对照组(P0.05),联合用药组与对照组治愈率分别为90.00%和83.33%,两组差异不显著(P0.05)。与对照组相比,联合用药组退热时间、咳嗽好转时间及肺部CT好转时间显著缩短(P0.05),两组患者治疗过程中病情加重情况差异不显著(P0.05)。结论较单纯抗病毒药物,清肺排毒汤加减方联合抗病毒药物能显著缩短COVID-19患者住院时间、临床症状好转时间及肺部CT好转时间。

Observation on clinical effect of modified Qingfei Paidu Decoction in treatment of COVID-19

Objective To study the clinical effect of modified Qingfei Paidu Decoction in the treatment of COVID-19. Methods Sixty patients who met the criteria for COVID-19 diagnosis and were discharged from the Third People''s Hospital of Hubei Province from January 24, 2020 to March 07, 2020 were selected. According to the different treatment methods, 30 patients in the combination group were given conventional treatment (nutritional support, respiratory support, and antiviral treatment) combined with modified Qingfei Paidu Decoction, while 30 patients in the control group were only given conventional treatment. The clinical cure rate, the time of main symptom disappearance, and the time of improvement of related detection indexes were compared in two groups. Results The hospitalization time in the combination treatment group was significantly lower than that in the control group (P<0.05). The cure rate of the combination group and control group were 90.00% and 83.33%, respectively. There was no statistically significant difference between the two groups (P>0.05). Compared with the control group, the antipyretic time, the improvement time of cough and lung CT in the combination treatment group was significantly shortened (P<0.05). There was no significant difference in the aggravation of the disease between the two groups (P>0.05). Conclusion Modified Qingfei Paidu Decoction combined with western medicine in the treatment of COVID-19 is more effective than the treatment of western medicine alone, which can significantly shorten the patient''s hospitalization time, clinical symptom improvement time and lung CT improvement time.